CoChat

Design Expert ® supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease

Kumar, Shobhit, Ali, Javed, Baboota, Sanjula · 2016 · Nanotechnology

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Selegiline is a monoamine oxidase B (MAO-B) inhibitor and is used in the treatment of Parkinson’s disease. The main problem associated with its oral administration is its low oral bioavailability (10%) due to its poor aqueous solubility and extensive first pass metabolism. The aim of the present research work was to develop a nanoemulsion loaded with selegiline for direct nose-to-brain delivery for the better management of Parkinson’s disease. A quality by design (QbD) approach was used in a statistical multivariate method for the preparation and optimization of nanoemulsion. In this study, four independent variables were chosen, in which two were compositions and two were process variables, while droplet size, transmittance, zeta potential and drug release were selected as response variables. The optimized formulation was assessed for efficacy in Parkinson’s disease using behavioural studies, namely forced swimming, locomotor, catalepsy, muscle coordination, akinesia and bradykinesia or pole test in Wistar rats. The observed droplet size, polydispersity index (PDI), refractive index, transmittance, zeta potential and viscosity of selegiline nanoemulsion were found to be 61.43 ± 4.10 nm, 0.203 ± 0.005, 1.30 ± 0.01, 99.80 ± 0.04%, −34 mV and 31.85 ± 0.24 mPas respectively. Surface characterization studies demonstrated a spherical shape of nanoemulsion which showed 3.7 times enhancement in drug permeation as compared to drug suspension. The results of behaviour studies showed that treatment of haloperidol induced Parkinson’s disease in rats with selegiline nanoemulsion (administered intranasally) showed significant improvement in behavioural activities in comparison to orally administered drug. These findings demonstrate that nanoemulsion could be a promising new drug delivery carrier for intranasal delivery of selegiline in the treatment of Parkinson’s disease.

Overview

Integrity signals

Registry

Crossref · 10.1088/0957-4484/27/43/435101

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 51 references

Cited by

See all 122

Metadata

Authors
Kumar, S., Ali, J., & Baboota, S.
Affiliations
Hamdard University (PK)
Corresponding author
Baboota, Sanjula
Venue
Nanotechnology
Published
2016-09-22
Volume
27
Issue
43
Pages
435101
ISSN
  • 0957-4484 (ISSN-L)
  • 1361-6528
OpenAlex
W2522509600
Cited by
115
References
51
Citations by year
2026: 5 · 2025: 9 · 2024: 21 · 2023: 13 · 2022: 12 · 2021: 14 · 2020: 16 · 2019: 12 · 2018: 8 · 2017: 5
FWCI
4.75
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nanotechnology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Indian Council of Medical Sciences (ICMR), New Delhi (45/29/2014-Nan/BMS)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
selegiline, nanoemulsions, Parkinson's disease, intranasal drug delivery, nose-to-brain delivery, quality by design, monoamine oxidase B inhibitors, oral bioavailability, behavioral assessment, drug permeation, droplet size, zeta potential
MeSH terms
Animals, Behavior, Animal, Emulsions, Olfactory Bulb, Parkinson Disease, Selegiline, Solubility, Rats, Wistar, Nanostructures, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design Expert ® supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease. https://app.cochat.ai/papers/10.1088/0957-4484/27/43/435101
The paper
Kumar, S., Ali, J., & Baboota, S. (2016). Design Expert ® supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease. Nanotechnology. https://doi.org/10.1088/0957-4484/27/43/435101

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.